The invention relates to a double-target CD19 and CD22
chimeric antigen receptor and application thereof, in particular to a
polynucleotide sequence which is selected from (1) a coding sequence comprising anti-CD22 and anti-CD19 single-chain antibodies which are connected sequentially, a coding sequence of a human CD8
hinge region, a coding sequence of human CD8
transmembrane region, a coding sequence of a human 41BB
intracellular region, a coding sequence of a human CD3 zeta
intracellular region and a
polynucleotide sequence of a coding sequence of a fragment, comprising an
extracellular domain III and a
extracellular domain IV, of an optional EGFR; and (2) a complementary sequence of the (1)
polynucleotide sequence. The invention further provides a relevant
fusion protein, a carrier comprising the coding sequence and application of the
fusion protein, the coding sequence and the carrier. The prepared CD19-CD22-BBzCAR-
T cell has a strong killing function to the specific tumor
cell, CD107a expression and
IFN gamma secretion are high, and the killing efficiency to the target
cell can reach about 80% under the situation that the
effector-target ratio is 10:1.